A Study of Optical Imaging With Light From Radiotracers in Cancer Patients
A Feasibility Study of Non-Invasive Cerenkov Luminescence Imaging in Patients With Cancer
1 other identifier
observational
102
1 country
1
Brief Summary
The purpose of this study is to test Cerenkov luminescence imaging, which is a different way to take pictures of thyroid cancer and/or any tumors with (existing or suspected) nodal metastases in the neck, supraclavicular, axillary and/or inguinal region.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Mar 2018
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 20, 2018
CompletedStudy Start
First participant enrolled
March 20, 2018
CompletedFirst Posted
Study publicly available on registry
April 2, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
March 1, 2027
April 28, 2026
April 1, 2026
9 years
March 20, 2018
April 27, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Feasibility of clinical Cerenkov luminescence imaging by achieving satisfactory imaging at least a rate of 80%
The primary objective is to explore the overall feasibility of clinical Cerenkov imaging on patients with any tumors with nodal metastases (existing or suspected) scheduled for routine clinical FDG PET or 131I therapy.
Through study completion, an average of 24 hours
Study Arms (1)
Thyroid cancer/nodal metastasis
Participants will have thyroid cancer and nodal metastasis in the neck, supraclavicular, axillary and/or inguinal area.
Interventions
Cerenkov luminescence imaging will be obtained from MSKCC patients who are scheduled for routine FDG PET scan or 131I therapy that emit a continuum of ultraviolet and visible light from the decay of certain radionuclides.
Eligibility Criteria
Potential participants will be identified by a member of the patient's treatment team, the protocol investigator, or research team.
You may qualify if:
- Participant is 18 years of age or old
- Participant must meet one of the following:
- Patients with thyroid cancer scheduled for thyroid ablation therapy with 131I
- Patients with any tumors with (existing or suspected) nodal metastases in the neck, supraclavicular, axillary and/or inguinal region who are scheduled to receive a clinical FDG PET/CT scan
- Patients with metastatic prostate cancer who are schedule for Xofigo therapy with 223Ra
- Patients scheduled to receive a standard of care 66Ga-DOTA-TATE or \[18f\]-PARPi PET scan in the Nuclear Medicine Clinic
- Patient undergoing Lu-DOTA TATE treatment in the Nuclear Medicine Clinic
You may not qualify if:
- Patients imaged for Cerenkov luminescence are going to be required to be in a darkened enclosure for at least 10 minutes and sit still during image acquisition. Any conditions that would prevent this will exclude the patients. This includes patients who unable to sit in a dark environment, have claustrophobic, inability to sit still for a few minutes
- Any other past medical, physiological or demographic concerns. This includes any patients with skin blemishes that are present at the dermis over the tumor, as these are of particular interest for use of this technique. This also includes open wounds on the area of interest.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Memorial Sloan Kettering Cancer Center
New York, New York, 10021, United States
Related Publications (1)
Pratt EC, Skubal M, Mc Larney B, Causa-Andrieu P, Das S, Sawan P, Araji A, Riedl C, Vyas K, Tuch D, Grimm J. Prospective testing of clinical Cerenkov luminescence imaging against standard-of-care nuclear imaging for tumour location. Nat Biomed Eng. 2022 May;6(5):559-568. doi: 10.1038/s41551-022-00876-4. Epub 2022 Apr 11.
PMID: 35411113DERIVED
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Jan Grimm, MD, PhD
Memorial Sloan Kettering Cancer Center
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 20, 2018
First Posted
April 2, 2018
Study Start
March 20, 2018
Primary Completion (Estimated)
March 1, 2027
Study Completion (Estimated)
March 1, 2027
Last Updated
April 28, 2026
Record last verified: 2026-04